Infanrix-Ipv

Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A, the active ingredient in Infanrix-Ipv, is a vaccine presented as an injectable suspension for intramuscular use. It prevents diphtheria, tetanus, pertussis and poliomyelitis in infants and children.

GNH USA supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix-Ipv is a combination vaccine that protects against several bacterial and viral diseases in the pediatric population. - Diphtheria: induces immunity that prevents diphtheria infection. - Tetanus: stimulates antibodies that protect against tetanus toxin. - Pertussis (whooping cough): generates immunity to Bordetella pertussis. - Poliomyelitis: provides protection against poliovirus types 1, 2 and 3.

Common vaccine reactions are usually mild and transient.

Common Side Effects: - Injection site pain: soreness at the injection site. - Redness or swelling: localized erythema. - Low‑grade fever: mild temperature rise within 24‑48 hours. - Irritability or crying: especially in infants. - Loss of appetite: temporary decrease in feeding.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare neurologic events post‑vaccination. - High fever (>40 °C): may be accompanied by rash. - Guillain‑Barré syndrome: extremely rare demyelinating disorder. - Encephalopathy: very rare inflammation of the brain.

Infanrix-Ipv should be administered according to national immunisation schedules and after evaluating individual health status. - Allergy assessment: verify no severe allergy to any vaccine component. - Acute illness: postpone vaccination if the child has a moderate or severe febrile illness. - Immunocompromised patients: consider reduced immunogenicity and consult a specialist. - Post‑vaccination monitoring: observe for at least 15 minutes for immediate reactions. - Concomitant vaccines: follow guidelines on spacing or co‑administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other medicines or biologics, influencing immune response or safety.

Major Interactions (Avoid): - Immunoglobulin therapy: may neutralise vaccine antigens and reduce efficacy. - Blood products administered within 48 hours: can interfere with antibody formation.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: may diminish immune response, requiring serologic testing. - Antipyretics taken prophylactically: could mask fever, but generally acceptable. - Live vaccines given concurrently: increase reactogenicity; schedule spacing as recommended. - Antibiotics: generally no effect, but severe infection may warrant postponement.